TGFB1 and colorectal carcinoma: Indeed, the TβRI/II small molecule kinase inhibitor galunisertib was found to block ERK‐mediated non‐canonical TGF‐β signaling in KRAS‐mutated CRC cells, inhibiting the increased migratory phenotype in vitro and liver metastasis in vivo.62